Katherine Mathews

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Katherine Mathews sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Katherine Mathews: 1 sponsored US clinical trial, 1 recruiting.

Katherine Mathews sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Muscular Dystrophy, with 1 trials.

Mid-pack sponsor footprint

Katherine Mathews is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING

Clinical Trial Readiness for the Dystroglycanopathies

NCT00313677

Therapeutic Areas

Muscular Dystrophy 1

What is open in the Katherine Mathews pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Muscular Dystrophy (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Katherine Mathews: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Katherine Mathews sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Katherine Mathews1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Katherine Mathews sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Katherine Mathews sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Katherine Mathews page

1 registered trials is a research-attention snapshot, not an endorsement of Katherine Mathews or any single study.

  • 1 of Katherine Mathews's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Muscular Dystrophy is the condition Katherine Mathews studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Muscular Dystrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Katherine Mathews pipeline card: 1 registered trials from official public datasets.Report a data error.